<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chlorpromazine versus clotiapine for schizophrenia - Mazhari, S - 2017 | Cochrane Library</title> <meta content="Chlorpromazine versus clotiapine for schizophrenia - Mazhari, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011810.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chlorpromazine versus clotiapine for schizophrenia - Mazhari, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011810.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011810.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Chlorpromazine versus clotiapine for schizophrenia" name="citation_title"/> <meta content="Shahrzad Mazhari" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Saeed Esmailian" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Armita Shah‐Esmaeili" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Ali S Goughari" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Azam Bazrafshan" name="citation_author"/> <meta content="Kerman University of Medical Sciences" name="citation_author_institution"/> <meta content="Morteza Zare" name="citation_author"/> <meta content="Shiraz University of Medical Sciences" name="citation_author_institution"/> <meta content="zare_morteza34@yahoo.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD011810.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011810.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011810.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011810.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Chlorpromazine [adverse effects, *therapeutic use]; Dibenzothiazepines [adverse effects, *therapeutic use]; Dyskinesia, Drug‐Induced [epidemiology]; Intention to Treat Analysis; Patient Dropouts [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Risk; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011810.pub2&amp;doi=10.1002/14651858.CD011810.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011810\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011810\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011810.pub2",title:"Chlorpromazine versus clotiapine for schizophrenia",firstPublishedDate:"Apr 7, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011810.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011810.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011810.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011810.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011810.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011810.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011810.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011810.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011810.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011810.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1580 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011810.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0170"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0115"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-sec-0153"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/table_n/CD011810StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/table_n/CD011810StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chlorpromazine versus clotiapine for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#CD011810-cr-0002">Shahrzad Mazhari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#CD011810-cr-0003">Saeed Esmailian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#CD011810-cr-0004">Armita Shah‐Esmaeili</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#CD011810-cr-0005">Ali S Goughari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#CD011810-cr-0006">Azam Bazrafshan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information#CD011810-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>Morteza Zare</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information/en#CD011810-sec-0181">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011810.pub2">https://doi.org/10.1002/14651858.CD011810.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011810-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011810-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011810-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011810-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011810-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011810-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011810-abs-0001" lang="en"> <section id="CD011810-sec-0001"> <h3 class="title" id="CD011810-sec-0001">Background</h3> <p>Schizophrenia is a chronic, disabling and severe mental disorder, characterised by disturbance in perception, thought, language, affect and motor behaviour. Chlorpromazine and clotiapine are among antipsychotic drugs used for the treatment of people with schizophrenia. </p> </section> <section id="CD011810-sec-0002"> <h3 class="title" id="CD011810-sec-0002">Objectives</h3> <p>To determine the clinical effects, safety and cost‐effectiveness of chlorpromazine compared with clotiapine for adults with schizophrenia. </p> </section> <section id="CD011810-sec-0003"> <h3 class="title" id="CD011810-sec-0003">Search methods</h3> <p>We searched Cochrane Schizophrenia's Trials Register (last update search 16/01/2016), which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO and clinical trials registries. There are no language, date, document type, or publication status limitations for inclusion of records in the Register. </p> </section> <section id="CD011810-sec-0004"> <h3 class="title" id="CD011810-sec-0004">Selection criteria</h3> <p>All randomised clinical trials focusing on chlorpromazine versus clotiapine for schizophrenia. We included trials meeting our selection criteria and reporting useable data. </p> </section> <section id="CD011810-sec-0005"> <h3 class="title" id="CD011810-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention‐to‐treat basis. For continuous data, we estimated the mean difference (MD) between groups and its 95% CI. We employed a random‐effects model for analyses. We assessed risk of bias for included studies and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD011810-sec-0006"> <h3 class="title" id="CD011810-sec-0006">Main results</h3> <p>We have included four studies, published between 1974 and 2003, randomising 276 people with schizophrenia to receive either chlorpromazine or clotiapine. The studies were poor at concealing allocation of treatment and blinding of outcome assessment. Our main outcomes of interest were clinically important change in global and mental state, specific change in negative symptoms, incidence of movement disorder (dyskinesia), leaving the study early for any reason, and costs. All reported data were short‐term (under six months' follow‐up). </p> <p>The trials did not report data for the important outcomes of clinically important change in global or mental state, or cost of care. Improvement in mental state was reported using the Positive and Negative Syndrome Scale (PANSS). When chlorpromazine was compared with clotiapine the average improvement scores for mental state using the PANSS total was higher in the clotiapine group (1 RCT, N = 31, MD 11.50 95% CI 9.42 to 13.58, very low‐quality evidence). The average change scores on the PANSS negative sub‐scale were similar between treatment groups (1 RCT, N = 21, MD ‐0.97 95% CI ‐2.76 to 0.82, very low‐quality evidence). There was no clear difference in incidence of dyskinesia (1 RCT, N = 68, RR 3.00 95% CI 0.13 to 71.15, very low‐quality evidence). Similar numbers of participants left the study early from each treatment group (3 RCTs, N = 158, RR 0.68 95% CI 0.24 to 1.88, very low‐quality evidence). </p> </section> <section id="CD011810-sec-0007"> <h3 class="title" id="CD011810-sec-0007">Authors' conclusions</h3> <p>Clinically important changes in global and mental state were not reported. Only one trial reported the average change in overall mental state; results favour clotiapine but these limited data are very difficult to trust due to methodological limitations of the study. The comparative effectiveness of chlorpromazine compared to clotiapine on change in global state remains unanswered. Results in this review suggest chlorpromazine and clotiapine cause similar adverse effects, although again, the quality of evidence for this is poor, making firm conclusions difficult. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011810-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011810-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011810-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011810-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011810-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011810-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011810-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011810-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011810-abs-0004" lang="en"> <h3>Direct comparison of two antipsychotics (chlorpromazine versus clotiapine) for treating schizophrenia </h3> <p><b>Review question</b> </p> <p>The aim of this review was to find good quality evidence comparing the efficacy of chlorpromazine versus clotiapine for schizophrenia. </p> <p><b>Background</b> </p> <p>Chlorpromazine is one of the first antipsychotics to successfully alleviate the symptoms of psychosis. It was introduced in the 1950s and is still one of the most commonly used antipsychotics. However, chlorpromazine can cause serious side effects, particularly unpleasant movement disorders, causing many people with schizophrenia to stop taking chlorpromazine. During the past 70 years newer medications have been developed and most clinicians now have a wide choice of drugs for managing schizophrenia, however, none cure, and all cause some sort of side effect. The choice of treatment is still challenging. Clotiapine is a newer antipsychotic drug, found to be effective for treating the symptoms of schizophrenia and also known to be effective for treating people with schizophrenia who are resistant to other medications, however, like chlorpromazine it can cause serious movement disorders. </p> <p><b>Searching for evidence</b> </p> <p>Cochrane Schizophrenia's Information Specialist ran an electronic search in January 2016, searching their specialised register for trials that randomised people with schizophrenia to receive either chlorpromazine or clotiapine. The search identified six reports. We inspected these reports and found four trials, published between 1974 and 2003, randomising 276 participants that could be included in the review. </p> <p><b>Main results</b> </p> <p>The four included trials were poorly conducted and did not report data for clinically important change in global or mental state, or cost of care. Improvement in overall mental state was reported and participants receiving clotiapine had better improvement scores than those receiving chlorpromazine. However the trials also reported data for improvement in the negative symptoms, no difference between the two treatments was found. Clotiapine did not cause more movement disorders than chlorpromazine, and similar numbers of participants left the trials early. </p> <p><b>Conclusions</b> </p> <p>There is some very low‐quality evidence that favours clotiapine over chlorpromazine for improving overall mental state. For other outcomes, including adverse effects, there is no evidence of a difference between these two antipsychotics. However these data are very difficult to draw conclusions from, only four small trials provided data and these were poorly conducted. We cannot draw conclusions on the comparative effectiveness of chlorpromazine versus clotiapine from such data. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011810-sec-0170" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011810-sec-0170"></div> <h3 class="title" id="CD011810-sec-0171">Implications for practice</h3> <section id="CD011810-sec-0171"> <section id="CD011810-sec-0172"> <h5 class="title">1. For people with schizophrenia</h5> <p>Where clotiapine is available it is unclear of its advantages over chlorpromazine. It may be better at improving mental state compared to chlorpromazine but data are really so limited and of such poor quality that it is impossible to be certain of this. Schizophrenia is such a potentially difficult and damaging illness that it is important to not dismiss older treatments and clotiapine may have its place in treatment of some people who it would 'suit'. People with schizophrenia and their families should expect better data than are available from the few existing trials. </p> </section> <section id="CD011810-sec-0173"> <h5 class="title">2. For clinicians</h5> <p>This review suggests effects of clotiapine and these effects may be important. We really do not have good data on any outcomes but almost none on global state, and service use. Where clotiapine is used, and there is a dilemma about whether to use it, clinicians could help increase data on the effects of this antipsychotic drug by organising its evaluation in real world settings. </p> </section> <section id="CD011810-sec-0174"> <h5 class="title">3. For policy makers</h5> <p>Where clotiapine is an available option for use for people with schizophrenia, this review gives no evidence to discourage its inclusion within policy except that the data, when compared with one benchmark antipsychotic ‐ chlorpromazine ‐ is surprisingly and disappointingly thin. </p> </section> </section> <h3 class="title" id="CD011810-sec-0175">Implications for research</h3> <section id="CD011810-sec-0175"> <section id="CD011810-sec-0176"> <h5 class="title">1. General</h5> <p>Better reporting of trials would have resulted in this review being more informative. We recognise that we are largely using standards of today to judge trials of the past but we anticipate that adherence to the CONSORT statement (<a href="./references#CD011810-bbs2-0042" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285:1987‐91. ">Moher 2001</a>) would improve the quality of reporting data for future research. </p> </section> <section id="CD011810-sec-0177"> <h5 class="title">2. Specific</h5> <p>Where clotiapine is available trials could be undertaken and, as this review shows, such studies are justified if the drug is in use. Long‐term effects are important. We realise that design of such a study takes time and methodical planning but we have given this some thought and outline a draft design (<a href="#CD011810-tbl-0004">Table 3</a>). </p> <div class="table" id="CD011810-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggestions for design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described<br/> Blindness: double, tested<br/> Duration: 12 months beyond end of intervention at least<br/> Raters: independent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: people with schizophrenia ‐ however diagnosed*<br/> Age: any<br/> Sex: both<br/> History: any<br/> N = 300** </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Clotiapine: ˜100 mg/day. N = 150<br/> 2. Chlorpromazine: ˜400 mg/day. N = 150 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global state ‐ relapse, clinically important change</p> <p>Mental state ‐ general ‐ clinically important change in mental state, average change in negative symptoms </p> <p>Adverse effects ‐ incidence of serious adverse events/effects, clinically important extrapyramidal symptoms </p> <p>Leaving the study early ‐ for any reason</p> <p>Cost of care</p> <p>Service outcomes: admitted, number of admissions, length of hospitalisation, discharge, contacts with psychiatric services<br/> Compliance with drugs<br/> Economic evaluations: cost‐effectiveness, cost‐benefit </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. </p> <p>**Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011810-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011810-sec-0029"></div> <div class="table" id="CD011810-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chlorpromazine compared to Clotiapine for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine compared with Clotiapine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> clotiapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clotiapine for schizophrenia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important change</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1a. General symptoms ‐ average change</b> <br/> (PANSS, short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average improvement scores in the intervention groups was<br/> <b>11.50 higher</b> <br/> (9.42 to 13.58 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐stated outcome of clinically important change in mental state not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2c. Specific ‐ average change score for negative symptoms</b> <br/> (PANSS ‐ negative short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>0.97 lower</b> <br/> (2.76 lower to 0.82 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: incidence of serious adverse effects.</b> Movement disorders ‐ dyskinesia ‐short‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.00</b> <br/> (0.13 to 71.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>243 per 1000</b> <br/> (168 to 354) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (46 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: clinically significant extrapyramidal symptoms</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: for any reason</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.68</b> <br/> (0.24 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>158<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> <br/> (31 to 961) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> <br/> (33 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost of care</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ downgraded by 1: study has an unclear risk of bias for random sequence generation, allocation concealment, or no wash‐out period reported, or source of funding unclear.<br/> <sup>2</sup>Imprecision: serious ‐ downgraded by 1: there are very few participants, number of events small<br/> <sup>3</sup>Publication bias: serious ‐ downgraded by 1: the study results only published in a local Japanese journal.<br/> <sup>4</sup>Inconsistency: serious ‐ downgraded by 1: there was high heterogeneity in the pooled results.<br/> <sup>5</sup>Indirectness: serious ‐ downgraded by 1: not direct measure of prespecified outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011810-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011810-sec-0030"></div> <section id="CD011810-sec-0031"> <h3 class="title" id="CD011810-sec-0031">Description of the condition</h3> <p>Schizophrenia can be a chronic, disabling and severe mental disorder that is characterised by disturbance in perception, thought, language, affect and motor behaviour. Common symptoms include hallucinations, delusions, disorganised speech, social withdrawal, flat affect and cognitive impairments. Lifetime prevalence of schizophrenia is around 0.87% (<a href="./references#CD011810-bbs2-0047" title="PeralaJ , SuvisaariJ , SaarniSI , KuoppasalmiK , IsometsaE , PirkolaS , et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry2007;64(1):19‐28. [PUBMED: 17199051] ">Perala 2007</a>). </p> </section> <section id="CD011810-sec-0032"> <h3 class="title" id="CD011810-sec-0032">Description of the intervention</h3> <p>Chlorpromazine was synthesised in 1951 by Paul Charpentier, and was the first drug that significantly alleviated symptoms of psychosis (<a href="./references#CD011810-bbs2-0011" title="BanTA . Fifty years chlorpromazine: a historical perspective. Neuropsychiatric Disease and Treatment2007;3(4):495‐500. [PUBMED: 19300578] ">Ban 2007</a>). Fifty years after its introduction, chlorpromazine is still one of the most commonly used antipsychotic drugs for management of people with schizophrenia (<a href="./references#CD011810-bbs2-0005" title="AdamsCE , RathboneJ , ThornleyB , ClarkeM , BorrillJ , WahlbeckK , et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine2005;3:15. [PUBMED: 16229742] ">Adams 2005</a>). Importantly, to evaluate a new drug for treatment of schizophrenia, studies often use chlorpromazine as a 'benchmark' drug (<a href="./references#CD011810-bbs2-0006" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a>). However, chlorpromazine is associated with adverse effects ranging from inducing seizure, sudden death, neuroleptic malignant syndrome as well as sedation, decreased libido, blurred vision, and orthostatic hypotension (<a href="./references#CD011810-bbs2-0046" title="PakpoorJ , AgiusM . A review of the adverse side effects associated with antipsychotics as related to their efficacy. Psychiatria Danubina2014;26 Suppl 1:273‐84. [PUBMED: 25413553] ">Pakpoor 2014</a>). </p> <p>Clotiapine has been manufactured since the late 1960s and is prescribed at least in Argentina, Belgium, Israel, Italy, South Africa, Spain, Switzerland and Taiwan for a range of conditions including schizophrenia, bipolar disorder (specifically mania) and other acute psychotic illnesses (<a href="./references#CD011810-bbs2-0013" title="BerkM , RathboneJ , Mandriota‐CarpenterS . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2] ">Berk 2004</a>). Clotiapine provides rapid treatment for the symptoms of schizophrenia, and its efficiency for people who are not responsive to other typical antipsychotics has been demonstrated (<a href="./references#CD011810-bbs2-0025" title="GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80(2‐3):343‐7. [PUBMED: 16126373] ">Geller 2005</a>). Like chlorpromazine and other typical antipsychotics, clotiapine is linked to a number of adverse effects including extrapyramidal syndromes and a strong sedative effect (<a href="./references#CD011810-bbs2-0025" title="GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80(2‐3):343‐7. [PUBMED: 16126373] ">Geller 2005</a>). </p> </section> <section id="CD011810-sec-0033"> <h3 class="title" id="CD011810-sec-0033">How the intervention might work</h3> <p>Chlorpromazine is a phenothiazine neuroleptic, 3‐(2‐chlorophenothiazin‐10‐yl)‐N, N‐dimethylpropan‐1‐amine (<a href="#CD011810-fig-0001">Figure 1</a>). Like many antipsychotics, chlorpromazine acts as an antagonist (or blocking agent) for a number of postsynaptic receptors, resulting in the broad range of effects noted previously. Chlorpromazine’s pharmacodynamics varies, but includes antagonist interactions with dopaminergic (especially the D2 subtype), and serotonergic 5‐hydroxytryptamine (5‐HT1 and 5‐HT2) postsynaptic receptors (<a href="./references#CD011810-bbs2-0010" title="AmatoD . Serotonin in antipsychotic drugs action. Behavioural Brain Research2015;277:125‐35. ">Amato 2015</a>; <a href="./references#CD011810-bbs2-0041" title="MiyamotoS , MiyakeN , JarskogLF , FleischhackerWW , LiebermanJA . Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry2012;17:1206‐27. ">Miyamoto 2012</a>). </p> <div class="figure" id="CD011810-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Chlorpromazine structure" data-id="CD011810-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Chlorpromazine structure</p> </div> </div> </div> <p>Clotiapine is a dibenzothiazepine neuroleptic, named 2‐chloro‐11‐(4‐methyl‐1‐piperazinyl) dibenzo[b,f][1,4]thiazepine (<a href="./references#CD011810-bbs2-0013" title="BerkM , RathboneJ , Mandriota‐CarpenterS . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2] ">Berk 2004</a>) (<a href="#CD011810-fig-0002">Figure 2</a>), and like chlorpromazine acts on multiple serotonergic and dopaminergic postsynaptic receptors. Clotiapine interacts with 5‐HT serotonin receptors in a number of ways, including acting as a blocking agent for 5‐HT3 and down‐regulating 5‐HT2 receptors (clotiapine has also been shown to possess a high affinity for 5HT‐6 receptors) (<a href="./references#CD011810-bbs2-0025" title="GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80(2‐3):343‐7. [PUBMED: 16126373] ">Geller 2005</a>). There is also evidence that clotiapine demonstrates limited blockage of dopaminergic D2 (<a href="./references#CD011810-bbs2-0044" title="MooreNC , GershonS . Which atypical antipsychotics are identified by screening tests?. Clinical Neuropharmacology1989;12:167‐84. ">Moore 1989</a>) and D4 receptors (<a href="./references#CD011810-bbs2-0054" title="ZawilskaJB , DerbiszewskaT , NowakJZ . Clozapine and other neuroleptic drugs antagonize the light‐evoked suppression of melatonin biosynthesis in chick retina: involvement of the D4‐like dopamine receptor. Neural Transmission1994;97:107‐17. ">Zawilska 1994</a>). </p> <div class="figure" id="CD011810-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Clotiapine structure" data-id="CD011810-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Clotiapine structure</p> </div> </div> </div> </section> <section id="CD011810-sec-0034"> <h3 class="title" id="CD011810-sec-0034">Why it is important to do this review</h3> <p>Chlorpromazine is often considered a 'benchmark' antipsychotic and is used worldwide for treatment of people with schizophrenia, thus, it is important to compare its therapeutic and side effects with other medications. To our knowledge, there is no systematic review comparing the clinical outcomes and side effects of chlorpromazine to clotiapine. </p> <p>The aim of this review is to compare chlorpromazine to clotiapine, which will then build up a series of Cochrane Reviews to give an overview of chlorpromazine's efficacy compared to other antipsychotics for the treatment of schizophrenia (<a href="#CD011810-tbl-0002">Table 1</a>). </p> <div class="table" id="CD011810-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The Cochrane chlorpromazine for people with schizophrenia reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acetophenazine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0012" title="BazrafshanA , ZareM , OkhovatiM , Shamsi MeimandiM . Acetophenazine versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD011662] ">Bazrafshan 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine dose for people with schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0039" title="LiuX , DeHaanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007778; PUBMED: 19370692] ">Liu 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cessation of medication for people with schizophrenia already stable on chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0008" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329; PUBMED: 17253586] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0048" title="SahaKB , SampsonS , ZamanRU . Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010631] ">Saha 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus clotiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0038" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; PUBMED: 18254045] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus metiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0053" title="ZareM , BazrafshanA , OkhovatiM , MazhariS , MousaviR . Chlorpromazine versus metiapine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 5. [DOI: 10.1002/14651858.CD011655] ">Zare 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus penfluridol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0035" title="KhaliliN , VahedianM , NikvarzN , PiriM . Chlorpromazine versus penfluridol for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD011831] ">Khalili 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus piperacetazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0023" title="Eslami ShahrbabakiM , SharafkhaniR , DehnaviehR , ValiL . Chlorpromazine versus piperacetazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011709] ">Eslami 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0006" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0007" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011810-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011810-sec-0035"></div> <p>To determine the clinical effects, safety and cost‐effectiveness of chlorpromazine compared with clotiapine for adults with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011810-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011810-sec-0036"></div> <section id="CD011810-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011810-sec-0038"> <h4 class="title">Types of studies</h4> <p>We considered all relevant randomised controlled trials (RCTs). If a trial was described as 'double‐blind' but implied randomisation, we included such trials in a sensitivity analysis (see <a href="#CD011810-sec-0109">Sensitivity analysis</a>). We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. If people were given additional treatments within chlorpromazine, we planned to only include data if the adjunct treatment was evenly distributed between groups and it was only the chlorpromazine that was randomised. </p> </section> <section id="CD011810-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. If we found a trial where there was a range of diagnoses, we only included it if the majority of participants had schizophrenia. </p> <p>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible, and so proposed to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD011810-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD011810-sec-0041"> <h5 class="title">1. Chlorpromazine</h5> <p>Any dose, any method of administration</p> </section> <section id="CD011810-sec-0042"> <h5 class="title">2. Clotiapine</h5> <p>Any dose, any method of administration</p> </section> </section> <section id="CD011810-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>We divided outcomes into short‐term (less than six months), medium‐term (7 to 12 months), and long‐term (over one year). </p> <section id="CD011810-sec-0044"> <h5 class="title">Primary outcomes</h5> <section id="CD011810-sec-0045"> <h6 class="title">1. Global state</h6> <p>1.1 Clinically significant improvement in global state, as defined by each study</p> </section> <section id="CD011810-sec-0046"> <h6 class="title">2. Mental state</h6> <p>2.1 Clinically important change in mental state, as defined by each study</p> </section> <section id="CD011810-sec-0047"> <h6 class="title">3. Adverse events</h6> <p>3.1 Incidence of clinically important movement disorder, as defined by each study</p> </section> </section> <section id="CD011810-sec-0048"> <h5 class="title">Secondary outcomes</h5> <section id="CD011810-sec-0049"> <h6 class="title">1. Global state</h6> <p>1.1 Average scores for global state<br/> 1.2 Relapse </p> </section> <section id="CD011810-sec-0050"> <h6 class="title">2. Mental state</h6> <p>2.1 General symptoms ‐ prevalence or average scores<br/> 2.2 Specific symptoms ‐ prevalence or average scores<br/> 2.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<br/> 2.2.2 Negative symptoms (avolition, poor self care, blunted affect)<br/> 2.2.3 Mood ‐ depression </p> </section> <section id="CD011810-sec-0051"> <h6 class="title">3. Adverse effects</h6> <p>3.1 General ‐ prevalence or average scores<br/> 3.2 Specific ‐ prevalence or average scores<br/> 3.2.1 Deaths by suicide or natural causes<br/> 3.2.2 Movement disorders (extrapyramidal side effects, specifically tardive dyskinesia and neuroleptic malignant syndrome)<br/> 3.2.3 Sedation<br/> 3.2.4 Dry mouth<br/> 3.2.5 Others ‐ categorised by system </p> </section> <section id="CD011810-sec-0052"> <h6 class="title">4. Leaving the study</h6> </section> <section id="CD011810-sec-0053"> <h6 class="title">5. Behaviour</h6> <p>5.1 General behaviour ‐ prevalence or average scores<br/> 5.2 Specific behaviour ‐ prevalence or average scores<br/> 5.2.1 Social functioning<br/> 5.2.2 Employment status during trial (employed/unemployed)<br/> 5.2.3 Occurrence of violent incidents (to self, others, or property) </p> </section> <section id="CD011810-sec-0054"> <h6 class="title">6. Service use</h6> <p>6.1 Days in hospital<br/> 6.2 Readmission due to relapse<br/> 6.3 Discharge from hospital (see <a href="#CD011810-sec-0185">Differences between protocol and review</a>) </p> </section> <section id="CD011810-sec-0055"> <h6 class="title">7. Quality of life</h6> <p>7.1 Important or average change in person's quality of life as defined by each study</p> </section> <section id="CD011810-sec-0056"> <h6 class="title">8. Satisfaction with care</h6> <p>8.1 Important or average change in satisfaction of participant or care provider as defined by each study </p> </section> <section id="CD011810-sec-0057"> <h6 class="title">9. Cost of care</h6> </section> <section id="CD011810-sec-0058"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD011810-bbs2-0049" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>) and used <a href="http://community.cochrane.org/tools/review-production-tools/gradepro-gdt" target="_blank">GRADEpro GDT</a> to export data from our review to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision‐making. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD011810-list-0001"> <li> <p>Global State ‐ clinically important change in global state as defined by each study</p> </li> <li> <p>Mental State ‐ general ‐ clinically important change in mental state as defined by each study </p> </li> <li> <p>Mental State ‐ specific ‐ average change in negative symptoms</p> </li> <li> <p>Adverse effects ‐ incidence of serious adverse events/effects</p> </li> <li> <p>Adverse effects ‐ clinically important extrapyramidal symptoms</p> </li> <li> <p>Leaving the study early ‐ for any reason</p> </li> <li> <p>Cost of care</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD011810-sec-0059"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011810-sec-0060"> <h4 class="title">Electronic searches</h4> <section id="CD011810-sec-0061"> <h5 class="title">1. Cochrane Schizophrenia's trials register</h5> <p>The Information Specialist (IS) searched Cochrane Schizophrenia's Study‐Based Register of Controlled Trials using the following search strategy. </p> <p>(Chlorpromazine AND Clotiapine) in Intervention Field of STUDY</p> <p>Cochrane Schizophrenia's register of trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> </section> </section> <section id="CD011810-sec-0062"> <h4 class="title">Searching other resources</h4> <section id="CD011810-sec-0063"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD011810-sec-0064"> <h5 class="title">2. Personal contact</h5> <p>For this review, we did not contact the first author of each included study for information regarding unpublished trials. </p> </section> </section> </section> <section id="CD011810-sec-0065"> <h3 class="title" id="CD011810-sec-0065">Data collection and analysis</h3> <section id="CD011810-sec-0066"> <h4 class="title">Selection of studies</h4> <p>ASG and SE independently inspected citations from the searches and identified relevant abstracts. SM and ASE independently re‐inspected a random 20% sample to ensure reliability. ASG and SE obtained and inspected the full reports of the abstracts meeting the review criteria. Again, SM and ASE re‐inspected a random 20% of reports in order to ensure reliable selection. If it had not been possible to resolve disagreement by discussion, we would have attempted to contact the authors of the study for clarification, and if we could not resolve the disagreement we would not have included the trial, but placed it in the table 'Characteristics of studies awaiting classification' until a resolution was made. We included studies that met our inclusion criteria and reported useable data. We would have excluded studies that either did not meet our inclusion criteria or met our inclusion criteria but did not report useable data. </p> </section> <section id="CD011810-sec-0067"> <h4 class="title">Data extraction and management</h4> <section id="CD011810-sec-0068"> <h5 class="title">1. Extraction</h5> <p>Review authors AB and MZ extracted data from all included studies. In addition, to ensure reliability, SM and ASG independently extracted data from a random sample of these studies, comprising 10% of the total. We extracted data presented only in graphs and figures whenever possible, but only included the data if two reviewers independently had the same result. We attempted to contact study authors through an open‐ended request in order to obtain missing information, or for clarification, whenever necessary. If studies had been multi‐centred, where possible, we would have extracted data relevant to each component centre separately. </p> </section> <section id="CD011810-sec-0069"> <h5 class="title">2. Management</h5> <section id="CD011810-sec-0070"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms provided by Cochrane Schizophrenia.</p> </section> <section id="CD011810-sec-0071"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p> <ul id="CD011810-list-0002"> <li> <p>the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD011810-bbs2-0040" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); </p> </li> <li> <p>the measuring instrument had not been written or modified by one of the trialists for that particular trial; </p> </li> <li> <p>the instrument was a global assessment of an area of functioning and not sub‐scores which were not, in themselves, validated or shown to be reliable. However there would be exceptions: we would include sub‐scores from mental state scales measuring positive and negative symptoms of schizophrenia. </p> </li> </ul> </p> <p>Ideally the measuring instrument should either be i. a self‐report, or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in 'Description of studies' in the Results section we have noted if this is the case or not. </p> </section> <section id="CD011810-sec-0072"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We intended to primarily use endpoint data, and only use change data if the former were not available. We would have, where necessary, combined endpoint and change data in the analysis as we planned to use mean differences (MDs) rather than standardised mean differences (SMDs) throughout (<a href="./references#CD011810-bbs2-0018" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD011810-sec-0073"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards: </p> <section id="CD011810-sec-0074"> <p><b>For change data</b></p> <p> <ul id="CD011810-list-0003"> <li> <p>We entered change data, as when continuous data are presented on a scale that included a possibility of negative values (such as change data), it was difficult to tell whether data were skewed or not. We presented and entered change data into statistical analyses. </p> </li> </ul> </p> </section> <section id="CD011810-sec-0075"> <p><b>For endpoint data from studies with fewer than 200 participants:</b></p> <p> <ul id="CD011810-list-0004"> <li> <p>When a scale started from the finite number 0, we subtracted the lowest possible value from the mean, and divided this by the standard deviation (SD). If this value was lower than 1, it strongly suggested a skew, and we would exclude such data. If this ratio was higher than 1 but below 2, there was a suggestion of skew. We would enter such data and test whether its inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2, we would include such data because skew was less likely (<a href="./references#CD011810-bbs2-0009" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD011810-bbs2-0029" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). </p> </li> <li> <p>If a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which could have values from 30 to 210) (<a href="./references#CD011810-bbs2-0033" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), we modified the calculation described above to take into account the scale starting point. In such cases skew is present if 2 SD &gt; (S ‐ S min), where S was the mean score and S min was the minimum score. </p> </li> </ul> </p> <p>(Please note, irrespective of the above rules, we would enter endpoint data from studies of at least 200 participants in the analysis because skewed data pose less of a problem in large studies). </p> </section> </section> <section id="CD011810-sec-0076"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD011810-sec-0077"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD011810-bbs2-0045" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or PANSS) (<a href="./references#CD011810-bbs2-0033" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this can be considered as a clinically significant response (<a href="./references#CD011810-bbs2-0037" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original study authors. </p> </section> <section id="CD011810-sec-0078"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for clotiapine. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved') we reported data where the left of the line indicated an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD011810-sec-0079"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Again review authors MZ and AB worked independently to assess risk of bias by using criteria described in the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> (<a href="./references#CD011810-bbs2-0030" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>) to assess trial quality. This set of criteria is based on evidence of associations between an overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group (SM). Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain, if possible, further information. We reported non‐concurrence in quality assessment, but if disputes arose as to which category a trial was to be allocated, again, we attempted to resolve by discussion. </p> </section> <section id="CD011810-sec-0080"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011810-sec-0081"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD011810-bbs2-0015" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios (ORs) and that ORs tend to be interpreted as RR by clinicians (<a href="./references#CD011810-bbs2-0017" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome/harmful outcome (NNTB/NNTH) statistic with its CIs is intuitively attractive to clinicians, but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD011810-bbs2-0032" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD011810-sec-0082"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated the MD between groups. We preferred not to calculate effect size measures (SMD). However, if scales of very considerable similarity were used, we would presume that there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD011810-sec-0083"> <h4 class="title">Unit of analysis issues</h4> <section id="CD011810-sec-0084"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster‐randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, study authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD011810-bbs2-0019" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, CIs unduly narrow, and statistical significance overestimated. This causes type I errors (<a href="./references#CD011810-bbs2-0014" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD011810-bbs2-0026" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>If clustering had not been accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. Where clustering was incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC (Design effect = 1 + (m‐1) * ICC) (<a href="./references#CD011810-bbs2-0020" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported we would assume it to be 0.1 (<a href="./references#CD011810-bbs2-0051" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICC and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD011810-sec-0085"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state, despite a wash‐out phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD011810-bbs2-0022" title="ElbourneD , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data from the first phase of cross‐over studies. </p> </section> <section id="CD011810-sec-0086"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented additional treatment arms in comparisons. If data were binary we simply added and combined within the two‐by‐two table. If data were continuous we would have combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> (<a href="./references#CD011810-bbs2-0029" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Where the additional treatment arms were not relevant, we did not use these data. </p> </section> </section> <section id="CD011810-sec-0087"> <h4 class="title">Dealing with missing data</h4> <section id="CD011810-sec-0088"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD011810-bbs2-0052" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would address this within the 'Summary of findings' table by downgrading quality. We also downgraded quality within the 'Summary of findings' table, should total loss be 25% to 50%. </p> </section> <section id="CD011810-sec-0089"> <h5 class="title">2. Binary</h5> <p>Where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an intention‐to‐treat analysis (ITT)). Where studies did not use an ITT analysis, we presented completer‐only data. </p> </section> <section id="CD011810-sec-0090"> <h5 class="title">3. Continuous</h5> <section id="CD011810-sec-0091"> <h6 class="title">3.1 Attrition</h6> <p>Where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we used and presented these data. </p> </section> <section id="CD011810-sec-0092"> <h6 class="title">3.2 Standard deviations</h6> <p>If SDs were not reported, we first tried to obtain the missing values from the study authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and CIs available for group means, and either P value or t value available for differences in mean, we could calculate them according to the rules described in the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> (<a href="./references#CD011810-bbs2-0029" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). When only the SE was reported, we calculated SDs by the formula SD = SE * square root (n). Chapters 7.7.3 (<a href="./references#CD011810-bbs2-0029" title="HigginsJPT , GreenS (editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>) and 16.1.3 (<a href="./references#CD011810-bbs2-0031" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>) of the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> present detailed formulas for estimating SDs from P values, t or F values, CIs, ranges, or other statistics. If these formulae did not apply, we would calculate the SDs according to a validated imputation method based on the SDs of the other included studies (<a href="./references#CD011810-bbs2-0024" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome, and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis, excluding imputed values. </p> </section> <section id="CD011810-sec-0093"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who leave trials early or are lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recent methods, such as multiple imputation or mixed‐effects models for repeated measurements (MMRM), have become more of a standard. While the latter methods seem to be somewhat better than LOCF (<a href="./references#CD011810-bbs2-0036" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We did not, therefore exclude studies based on the statistical approach used but preferred more sophisticated approaches. For example, We preferred MMRM or multiple‐imputation to LOCF, and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the 'Incomplete outcome data' domain of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD011810-sec-0094"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD011810-sec-0095"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise, and would have fully discussed outliers. </p> </section> <section id="CD011810-sec-0096"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise and would have discussed such methodological outliers if they arose. </p> </section> <section id="CD011810-sec-0097"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD011810-sec-0098"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD011810-sec-0099"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD011810-bbs2-0028" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects, and ii. strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a CI for I<sup>2</sup>). We would have interpreted an I<sup>2</sup> estimate greater than or equal to around 50%, accompanied by a statistically significant Chi<sup>2</sup> test as statistical evidence of substantial levels of heterogeneity (<a href="./references#CD011810-bbs2-0018" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). If we had found substantial levels of heterogeneity in the primary outcome, we would have explored reasons for heterogeneity (<a href="#CD011810-sec-0104">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD011810-sec-0100"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD011810-sec-0101"> <h5 class="title">1. Protocol versus full study</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> (<a href="./references#CD011810-bbs2-0050" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). We tried to locate protocols of included randomised trials. If the protocol was available, we compared outcomes in the protocol with those in the published report. If the protocol was not available, we compared outcomes listed in the methods section of the trial report with actually reported results. </p> </section> <section id="CD011810-sec-0102"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD011810-bbs2-0021" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> (<a href="./references#CD011810-bbs2-0050" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We would not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In future versions if funnel plots are possible, we will seek statistical advice in their interpretation. </p> </section> </section> <section id="CD011810-sec-0103"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model; it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose a random‐effects model for all analyses. </p> </section> <section id="CD011810-sec-0104"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD011810-sec-0105"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD011810-sec-0106"> <h6 class="title">1.1 Primary outcomes</h6> <p>We did not anticipate any subgroup analyses.</p> </section> <section id="CD011810-sec-0107"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of chlorpromazine compared with clotiapine for people with schizophrenia in general. In addition, however, if relevant data had been available we would have reported data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD011810-sec-0108"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency had been high, we would have reported this. First, we would have investigated whether data had been entered correctly. Second, if data were correct, we would have visually inspected the graph, and successively removed studies outside of the company of the rest to see if homogeneity was restored. For this review we decided that, should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would have presented such data. If not, we would not pool data, but would have discussed the issues. We knew of no supporting research for this 10% cut‐off, but were investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to clinical or methodological heterogeneity. </p> </section> </section> <section id="CD011810-sec-0109"> <h4 class="title">Sensitivity analysis</h4> <section id="CD011810-sec-0110"> <h5 class="title">1. Implication of randomisation</h5> <p>We would have included trials in a sensitivity analysis if they had been described in some way as to imply randomisation. For the primary outcomes, if there had been no substantive difference when we added the implied randomised studies to those with better descriptions of randomisation, then we would have employed all data from these studies. If there was a substantive difference then we would have presented these data as 'other data'. </p> </section> <section id="CD011810-sec-0111"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD011810-sec-0087">Dealing with missing data</a>) we compared the findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study to that point. If there had been a substantial difference, we would have reported results and discussed them, but continued to employ our assumptions. </p> <p>If assumptions were needed regarding missing SDs (see <a href="#CD011810-sec-0087">Dealing with missing data</a>), we would have compared the findings of the primary outcomes when we used our assumptions and when we used data only from people who completed the study to that point. We would have undertaken a sensitivity analysis, testing how prone results were to change when we only compared completer‐only data to the imputed data using the above assumptions. If there had been a substantial difference, we would have reported results and discussed them, but continued to employ our assumptions. </p> </section> <section id="CD011810-sec-0112"> <h5 class="title">3. Risk of bias</h5> <p>We would have analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains (see <a href="#CD011810-sec-0079">Assessment of risk of bias in included studies</a>) for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we would have included data from these trials in the analysis. </p> </section> <section id="CD011810-sec-0113"> <h5 class="title">4. Imputed values</h5> <p>We would have undertaken a sensitivity analysis to assess the effects of including data from trials if we had used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not pool data from the excluded trials with the other trials contributing to the outcome, but would present them separately. </p> </section> <section id="CD011810-sec-0114"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <p>We synthesised all data using a random‐effects model. However, we also synthesised data for the primary outcome using a fixed‐effect model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011810-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011810-sec-0115"></div> <section id="CD011810-sec-0116"> <h3 class="title">Description of studies</h3> <section id="CD011810-sec-0117"> <h4 class="title">Results of the search</h4> <p>The PRISMA table shows results of our search <a href="#CD011810-fig-0003">Figure 3</a> (<a href="./references#CD011810-bbs2-0043" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097] ">Moher 2009</a>). </p> <div class="figure" id="CD011810-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram of trial selection from 2016 electronic search" data-id="CD011810-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of trial selection from 2016 electronic search</p> </div> </div> </div> <p>In the original search we found six reports that were potentially relevant. After removing two duplicates, we inspected full texts of the remaining four reports. </p> </section> <section id="CD011810-sec-0118"> <h4 class="title">Included studies</h4> <p>All four full‐text articles referred to individual studies and we were able to include all four studies. </p> <section id="CD011810-sec-0119"> <h5 class="title">1. Methods</h5> <p>One study was a cross‐over trial (<a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a>) and the three remaining studies were parallel trials (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>; <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>; <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a>). All included studies were randomised ‐ one, <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>, implied randomisation. </p> </section> <section id="CD011810-sec-0120"> <h5 class="title">2. Length of trials</h5> <p>Trial duration ranged from four weeks (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>) to 12 weeks (<a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a>, <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a>). </p> </section> <section id="CD011810-sec-0121"> <h5 class="title">3. Participants</h5> <p>Three studies reported that they included people with schizophrenia, one (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>) included participants with acute psychotic syndromes including "schizophrenic type" illnesses. Only <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> reported the diagnostic criteria ("cases with catatonic excitation, marked irritability, violence and manneristic act; hallucination; delusion; deficiency of initiative and apathy") and described the symptoms required for participants to be included in the study. In total, we included 276 participants in this review. </p> </section> <section id="CD011810-sec-0122"> <h5 class="title">4. Setting</h5> <p>All included studies were conducted in hospitals.</p> </section> <section id="CD011810-sec-0123"> <h5 class="title">5. Study size</h5> <p>The average number of participants was 69, ranging from 49 (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>) to 101 (<a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a>). </p> </section> <section id="CD011810-sec-0124"> <h5 class="title">6. Intervention</h5> <section id="CD011810-sec-0125"> <h6 class="title">6.1 Chlorpromazine</h6> <p>All the included studies compared chlorpromazine with clotiapine. The doses of chlorpromazine in the included studies ranged from 40 mg/day to 600 mg/day. The mean dose of chlorpromazine provided by <a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a> was 404.5 mg/day (). </p> </section> <section id="CD011810-sec-0126"> <h6 class="title">6.2 Clotiapine</h6> <p>The doses of clotiapine in the included studies ranged from 40 mg/day (<a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>) to 240 mg/day (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>; <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>). The mean dose was 125.2 mg/day in <a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>. The other studies provided no further details for the prescribed dose of the medication. </p> </section> <section id="CD011810-sec-0127"> <h6 class="title">6.3 Other treatments</h6> <p><a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a> also included one more treatment arm, thioridazine, in addition to chlorpromazine and clotiapine. We did not include data from this group. </p> </section> </section> <section id="CD011810-sec-0128"> <h5 class="title">7. Outcomes</h5> <p>Binary and continuous data were available. Outcomes reported by the studies included mental state, leaving the study early and adverse events. None of the included studies reported global state, quality of life, cost of care or behaviour. </p> <section id="CD011810-sec-0129"> <h6 class="title">7.1 Outcome scales</h6> <p>The following scales provided continuous data for the analyses.</p> <section id="CD011810-sec-0130"> <p><b>7.1.2 Mental state</b></p> <p>i. Positive and Negative Syndrome Scale (PANSS) (<a href="./references#CD011810-bbs2-0034" title="KaySR , FiszbeinA , OpferLA . The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin1987;13(2):261‐76. ">Kay 1987</a>) </p> <p>A brief rating scale used to assess the severity of positive and negative symptoms of schizophrenia, this scale has been reported as an operationalised, drug‐sensitive instrument, providing balanced representation of positive and negative symptoms as well as measuring their relationship to one another. Using PANSS, the patient is rated from 1 to 7 on 30 different symptoms based on interview in addition to reports of family members or clinical staff. PANSS scores can range from 30 to 210, high scores indicating more severity of positive, negative or global psychopathology. </p> <p>ii. Martens' Symptom Scale (S‐Scale) (<a href="./references#CD011810-bbs2-0027" title="HelgasonT . Methodology in Evaluation of Psychiatric Treatment. Cambridge: Cambridge University Press, 1983. ">Helgason 1983</a>) </p> <p>This scale is designed for measuring possible improvements in people with schizophrenia. This scale comprises 23 items, measuring severity of signs or symptoms. Two items are bipolar with 9 possible scores, the others are unipolar with 5 possible scores (ranging from absence to high severity of a sign or a symptom). </p> </section> </section> </section> </section> <section id="CD011810-sec-0131"> <h4 class="title">Excluded studies</h4> <p>We did not exclude any studies. This was partly because the search was very specific.</p> <section id="CD011810-sec-0132"> <h5 class="title">Awaiting assessment</h5> <p>No studies are awaiting assessment.</p> </section> <section id="CD011810-sec-0133"> <h5 class="title">Ongoing studies</h5> <p>We did not identify any ongoing studies.</p> </section> </section> </section> <section id="CD011810-sec-0134"> <h3 class="title">Risk of bias in included studies</h3> <p>Please also see <a href="#CD011810-fig-0004">Figure 4</a> and <a href="#CD011810-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD011810-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011810-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD011810-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011810-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD011810-sec-0135"> <h4 class="title">Allocation</h4> <p>Three studies (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>, <a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a>, <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a>) were randomised, however only <a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a> reported the method used for generating random allocation. In <a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a> participants were randomised by pre‐established randomised codes. None of these three studies described how allocation was concealed. <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> did not provide clear information for either randomisation or allocation concealment. Randomisation was implied and we rated this study high risk for selection bias. </p> </section> <section id="CD011810-sec-0136"> <h4 class="title">Blinding</h4> <p><a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>, <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> and <a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a> were double‐blind and had low risks of bias for performance bias. Identical capsules and tablets were reported as the most common procedure for blinding both participants and personnel. <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a> had high risk of performance bias as it reported that due to administrative and staff shortage, they couldn't introduce any blind procedures into the trial. Detection bias (blinding of outcome assessment) varied. <a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a> was low risk, reporting that trained observers were blind to the participants' treatment status. <a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a> was high risk, mentioning that a separate envelope for each participant was provided, in case it should be necessary to know what drug an individual participant was receiving, and <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> was at unclear risk of bias, with no clear information regarding blinding of outcome assessment. </p> </section> <section id="CD011810-sec-0137"> <h4 class="title">Incomplete outcome data</h4> <p>Three included studies (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>; <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>; <a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a>) had low risk of bias for incomplete outcome data. Only <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a> did not provide information about missing data and participants who left the study early. </p> </section> <section id="CD011810-sec-0138"> <h4 class="title">Selective reporting</h4> <p>Two studies (<a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a>; <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>) reported data for all outcomes. <a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a> and <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a> did not provide pre‐specified outcomes so it is unclear if they reported all outcomes. </p> </section> <section id="CD011810-sec-0139"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a> was financially supported by a research grant from Stanley Medical Research Institute and had no wash‐out period for the study. <a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a> and <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a> declared who supplied their drugs but did not report the source of funding. <a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> was also unclear about their funding source. </p> </section> </section> <section id="CD011810-sec-0140"> <h3 class="title" id="CD011810-sec-0140">Effects of interventions</h3> <p>See: <a href="./full#CD011810-tbl-0001"><b>Summary of findings for the main comparison</b> Chlorpromazine compared to Clotiapine for schizophrenia</a> </p> <p>Studies relevant to this review fell into a single comparison. We were able to extract numerical data from four randomised studies. </p> <section id="CD011810-sec-0141"> <h4 class="title">1. Comparison 1: chlorpromazine versus clotiapine</h4> <section id="CD011810-sec-0142"> <h5 class="title">1.1 Mental state: 1a. General symptoms ‐ average change score (PANSS total, high = good) </h5> <p>For this outcome we found a single study, with a total of 31 people. We found evidence of a clear difference, favouring clotiapine, between chlorpromazine and clotiapine (MD 11.50, 95% CI 9.42 to 13.58, <a href="./references#CD011810-fig-0006" title="">Analysis 1.1</a>). </p> </section> <section id="CD011810-sec-0143"> <h5 class="title">1.2 Mental state: 1b. General symptoms ‐ average change score (S‐scale, high = poor)</h5> <p>There was a clear difference, favouring chlorpromazine between chlorpromazine and clotiapine (1 RCT, N = 38, MD 1.45, 95% CI 0.38 to 2.52, <a href="./references#CD011810-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD011810-sec-0144"> <h5 class="title">1.3 Mental state: 2a. Specific ‐ positive symptoms ‐ frequency</h5> <p>A single study (<a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a>) reported incidence of positive and negative symptoms (<a href="./references#CD011810-fig-0008" title="">Analysis 1.3</a>). </p> <p>We found no evidence of a clear difference between chlorpromazine and clotiapine for several specific symptoms (<a href="./references#CD011810-fig-0008" title="">Analysis 1.3</a>). </p> <p>1.3.1 Delusions: 1 RCT, N = 12, RR 1.33, 95% CI 0.50 to 3.55</p> <p>1.3.2 Hallucinations: 1 RCT, N = 25, RR 0.46, 95% CI 0.15 to 1.40</p> <p>1.3.3 Severe excitation: 1 RCT, N = 5, RR 0.75, 95% CI 0.15 to 3.72</p> </section> <section id="CD011810-sec-0145"> <h5 class="title">1.4 Mental state: 2a. Specific ‐ positive symptoms ‐ average change score (PANSS‐positive, high = good) </h5> <p><a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> also provided mental state data, reporting the average change scores on the PANSS for both positive and negative symptoms. </p> <p>For delusions we found evidence of a clear effect, favouring clotiapine (1 RCT, N = 11, MD 7.36, 95% CI 3.54 to 11.18) but no effect for the outcome of 'hallucinations' (1 RCT, N = 16, MD ‐3.00, 95% CI ‐6.75 to 0.75, <a href="./references#CD011810-fig-0009" title="">Analysis 1.4</a>). </p> </section> <section id="CD011810-sec-0146"> <h5 class="title">1.5 Mental state: 2c. Specific ‐ negative symptoms ‐ average change scores (PANSS‐negative, high = good) </h5> <p>For the outcome of 'deficiency of initiative and apathy' we found no evidence of a clear difference between chlorpromazine and clotiapine (MD ‐0.97, 95% CI ‐2.76 to 0.82, <a href="./references#CD011810-fig-0010" title="">Analysis 1.5</a>). </p> </section> <section id="CD011810-sec-0147"> <h5 class="title">1.6 Mental state: 2d. Specific ‐ various symptoms ‐ average change score (S‐Scale, high = poor) </h5> <p><a href="./references#CD011810-bbs2-0001" title="JacobssonL , NordnMB . A controlled trial of clotiapine and chlorpromazine in acute schizophrenic syndromes. Acta Psychiatrica Scandinavica1974;Suppl. 255:55‐71. ">Jacobsson 1974</a> (N = 49) measured mental state using Martens' Symptom Scale (S‐Scale). Findings were varied. For the outcome of 'delusions' we did not find evidence that chlorpromazine was clearly different in its effects compared with clotiapine (1 RCT, N = 38, MD ‐0.06, 95% CI ‐0.3 to 0.18). For 'hallucinations', however, we did find evidence of an effect, favouring clotiapine (1 RCT, N = 38, MD ‐0.24, 95% CI ‐0.46 to ‐0.02, <a href="./references#CD011810-fig-0011" title="">Analysis 1.6</a>). We also found evidence that chlorpromazine was better in its effects compared with clotiapine for 'influence of thought' (1 RCT, N = 38, MD 0.28, 95% CI 0.17 to 0.39) but no evidence of a clear difference between chlorpromazine and clotiapine for 'splitting' (1 RCT, N = 38, MD 0.01, 95% CI ‐ 0.09 to 0.11, <a href="./references#CD011810-fig-0011" title="">Analysis 1.6</a>). </p> </section> <section id="CD011810-sec-0148"> <h5 class="title">1.7 Adverse effects 1. Central nervous system ‐ short term</h5> <p><a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> (N = 68) reported on several general central nervous system effects. The study did not find evidence of a clear difference between chlorpromazine and clotiapine for drowsiness (RR 1.89, 95% CI 0.98 to 3.63), somnipathy (RR 1.38, 95% CI 0.63 to 2.99), unsteadiness (RR 1.71, 95% CI 0.77 to 3.82) nor weakness (RR 0.75, 95% CI 0.42 to 1.34, <a href="./references#CD011810-fig-0012" title="">Analysis 1.7</a>). </p> </section> <section id="CD011810-sec-0149"> <h5 class="title">1.8 Adverse effects: 2. Movement disorders ‐ short term</h5> <p>There was not a clear difference between chlorpromazine and clotiapine for the outcome of akathisia (1 RCT, N = 68, RR 3.00, 95% CI 0.65 to 13.83), dyskinesia (1 RCT, N = 68, RR 3.00, 95% CI 0.13 to 71.15) nor Parkinsonism (2 RCTs, N = 106, RR 1.17, 95% CI 0.87 to 1.57, <a href="./references#CD011810-fig-0013" title="">Analysis 1.8</a>). </p> </section> <section id="CD011810-sec-0150"> <h5 class="title">1.9 Adverse effects: 3. Various other ‐ short term</h5> <p><a href="./references#CD011810-bbs2-0002" title="KanekoJ , TanimukaiH , KudoY . A double‐blind, controlled study of the effects of clotiapine and chlorpromazine on schizophrenia. Clinical Psychiatry1969;11(9):721‐8. ">Kaneko 1969</a> (N = 68) reported 'weight gain (of not less than 3 kg at the end of study)' and did not find a clear difference between chlorpromazine and clotiapine (RR 1.12, 95% CI 0.71 to 1.75). The same study also reported 'thirst' and, again, found no clear difference between the drugs (RR 1.29, 95% CI 0.54 to 3.06, <a href="./references#CD011810-fig-0014" title="">Analysis 1.9</a>). </p> </section> <section id="CD011810-sec-0151"> <h5 class="title">1.10 Leaving the study early ‐ short term</h5> <p>Around 17% left the studies but there was no clear difference between chlorpromazine and clotiapine (3 RCTs, N = 158, RR leaving for any reason 0.68, 95% CI 0.24 to 1.88), this outcome had moderate levels of heterogeneity (I<sup>2</sup> = 47%). Attrition fell to about 14% when the reason of 'due to deterioration or adverse effects' was reported (2 RCTs, N = 117, RR 1.23, 95% CI 0.51 to 2.99) but there was still no difference between groups (<a href="./references#CD011810-fig-0015" title="">Analysis 1.10</a>). </p> </section> <section id="CD011810-sec-0152"> <h5 class="title">1.11 Service use: discharge from hospital ‐ short term (12 weeks)</h5> <p>Only <a href="./references#CD011810-bbs2-0004" title="VanWykAJ , MarisGFT . Chlorpromazine, clotiapine and thioridaz ‐ a comparative clinical trial on Bantu psychotic patients. South African Medical Journal1971;45:945‐7. ">Van Wyk 1971</a> (N = 70), reported data on numbers of participants discharged from hospital by 12 weeks. There is evidence of an effect favouring clotiapine for this outcome (RR 1.49, 95% CI 1.07 to 2.08, <a href="./references#CD011810-fig-0016" title="">Analysis 1.11</a>). </p> <p>We also performed analysis of subclasses of mental state by positive symptoms and the results are reported in <a href="#CD011810-tbl-0003">Table 2</a>. </p> <div class="table" id="CD011810-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mental state: improvement for positive symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcome or subgroup</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Statistical method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Effect estimate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: average scores for improvement of positive symptoms (high score = improvement)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.17 [‐7.98, 12.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.00 [‐6.75, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.36 [3.54, 11.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: Improved positive symptoms (frequency of marked effects)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 [0.41, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 [0.15, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 [0.50, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Severe excitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 [0.15, 3.72]</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011810-sec-0153" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011810-sec-0153"></div> <section id="CD011810-sec-0154"> <h3 class="title" id="CD011810-sec-0154">Summary of main results</h3> <p>The summary below refers to the outcomes selected for <a href="./full#CD011810-tbl-0001">summary of findings Table for the main comparison</a>, and highlights the important findings of this review for evidence‐based decision making. </p> <section id="CD011810-sec-0155"> <h4 class="title">1. Global state</h4> <p>We could not extract any usable data from the trials comparing chlorpromazine with clotiapine, therefore it is not possible to draw any conclusions about whether clotiapine is more or less effective in improving the global state of people with schizophrenia. This is a real omission of even the few trials we have identified. </p> </section> <section id="CD011810-sec-0156"> <h4 class="title">2. Mental state: general</h4> <p>Only one trial specifically reported mental state as measured by the PANSS total scores. Results favoured efficacy of chlorpromazine compared with clotiapine but these are short‐term, very low‐quality data, from one tiny trial, reporting a proxy outcome (continuous measure rather than binary), the interpretation of which is problematic in clinical life. A meta‐analysis of three randomised trials that evaluated the global improvements in people with acute psychotic disorders ‐ rather than more narrowly defined and stable schizophrenia ‐ indicated no distinct superiority of clotiapine compared with other standard treatments like chlorpromazine (<a href="./references#CD011810-bbs2-0013" title="BerkM , RathboneJ , Mandriota‐CarpenterS . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2] ">Berk 2004</a>). At best, this current review suggests no dramatic difference between the two compounds. </p> </section> <section id="CD011810-sec-0157"> <h4 class="title">3. Mental state: specific</h4> <p>Our findings fail to indicate a clear difference between the efficacy of chlorpromazine versus clotiapine for improving negative symptoms, and both drugs were not effective in improving negative symptoms. This is an important outcome and there is little convincing evidence from any comparison of any treatment for people with schizophrenia that negative symptoms are responsive to drugs. The call for larger, longer, better trials in this area is not specific to the comparison which was the focus of this review. </p> </section> <section id="CD011810-sec-0158"> <h4 class="title">4. Adverse effects: incidence of movement disorders, and clinically significant extrapyramidal symptoms </h4> <p>For the limited data we had to work with, chlorpromazine and clotiapine seem to produce a similar profile of movement disorders in people with schizophrenia. However, another review suggested that clotiapine may induce fewer movement disorders (Parkinsonism symptoms) (<a href="./references#CD011810-bbs2-0013" title="BerkM , RathboneJ , Mandriota‐CarpenterS . Clotiapine for acute psychotic illnesses. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD002304.pub2] ">Berk 2004</a>). This is important and merits further investigation of safety and tolerability profiles. </p> </section> <section id="CD011810-sec-0159"> <h4 class="title">5. Leaving the study early</h4> <p>These studies were short. Around 17% of both groups left early (any reason) and 14% when it came to the specific reason of deterioration or adverse effects. These figures compare favourably to many of the more modern trials where attrition rate is far greater ‐ even over a matter of a few weeks. There seems to be no implication in the studies that attrition was for different reasons in each group. More detailed information would have been helpful and it might have been possible to extract outcome data, even on those who left. Nevertheless, we found no evidence that one or other drug was more unacceptable to either trial participants, or researchers. </p> </section> <section id="CD011810-sec-0160"> <h4 class="title">7. Service use</h4> <p>At the end of 12 weeks in one study around 80% of people receiving clotiapine were able to be discharged from hospital compared with around 50% receiving chlorpromazine. This was statistically significant. If reproduced this is a most important result. If clotiapine is genuinely faster at getting people better this is very important with enormous implications. This result needs to be reinvestigated. </p> </section> <section id="CD011810-sec-0161"> <h4 class="title">6. Cost of care</h4> <p>Again, we could not extract any usable data from the trials comparing chlorpromazine with clotiapine, therefore it is not possible to draw any conclusions about whether chlorpromazine is more or less effective than clotiapine in terms of cost. However, as there is little difference in the cost of the drugs, all else being equal, then service use is a good proxy for cost. Should the finding for service use be true and clotiapine really does get people better, faster, then savings by use of clotiapine would be huge. </p> </section> </section> <section id="CD011810-sec-0162"> <h3 class="title" id="CD011810-sec-0162">Overall completeness and applicability of evidence</h3> <section id="CD011810-sec-0163"> <h4 class="title">1. Completeness</h4> <p>There are some relevant limitations for the conclusions of this meta‐analysis, which should be pointed out. Of the four included studies, almost all of them provided some data on the primary outcomes mental state and adverse effects. However, no study reported usable data for the primary outcome 'global state'. Therefore, the evidence on this primary outcome is not complete. In addition, only three studies reported on secondary outcomes. The evidence on prespecified adverse effects is particularly incomplete, as none of the included trials specifically reported important side effects such as death, suicide or cardiac effects. There were also no usable data on behaviour, quality of life, service use, satisfaction with care or cost of care. The total number of participants in the included studies is extremely limited, which can lead to inconclusive results (<a href="./references#CD011810-bbs2-0016" title="Davey SmithG , EggerM . Meta‐analysis: unresolved issues and future developments. BMJ1998;16:221‐5. ">Davey Smith 1998</a>), regardless of whether the estimations were significant. Therefore, new large trials with better outcome reporting are needed for clear interpretation and precise decisions about the differences between the efficacy of chlorpromazine and clotiapine. These outcomes do not need to depend on sophisticated rating but could be clear, binary and pragmatic. </p> </section> <section id="CD011810-sec-0164"> <h4 class="title">2. Applicability</h4> <section id="CD011810-sec-0165"> <h5 class="title">2.1 Diagnosis</h5> <p>All of the included studies except <a href="./references#CD011810-bbs2-0003" title="BelmakerR . Clotiapine for schizophrenia. Stanley Foundation Research Programs2006. GellerV , GorzaltsanI , ShleiferT , BelmakerRH , BersudskyY . Clotiapine compared with chlorpromazine in chronic schizophrenia. Schizophrenia Research2005;80:343‐7. SchlieferT , BersudskyY , GellerV , BelmakerRH . Clotiapine in schizophrenia: a controlled study. 16th European College of Neuropsychopharmacology Congress. Prague, Czech Republic, 2003. ">Schliefer 2003</a> were conducted over 40 years ago, which could have led to serious limitations for applicability of this review. Almost all the included studies in this review provided less rigorous criteria for diagnosis of schizophrenia than would, perhaps, be seen in more modern trials. It is likely that some included participants in those studies would reflect other diagnosis than schizophrenia. However, this is rather like normal clinical practice where diagnosis is not an exact science. </p> </section> <section id="CD011810-sec-0166"> <h5 class="title">2.2 Setting</h5> <p>All included studies were conducted in hospitals and inpatient settings. However, today much schizophrenia is diagnosed and treated in the early stages in the community, which could reduce the applicability of this review for current practice. </p> </section> </section> </section> <section id="CD011810-sec-0167"> <h3 class="title" id="CD011810-sec-0167">Quality of the evidence</h3> <p>The data reported are limited and poor quality; we rated available evidence as very low based on GRADE (<a href="./references#CD011810-bbs2-0049" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). Three studies stated that they were randomised and provided information about how this was achieved. One study said it was randomised but provided no information about the randomisation method. Three studies had serious risk of bias for allocation concealment. One study was not blinded. Two studies reported that the assessor was not blinded to which drug the participants were receiving. We also detected inconsistency, imprecision and serious publication bias detected for two studies. None of the included studies reported usable data for most important outcomes as they provided no standard deviation or standard error of mean for estimations. </p> </section> <section id="CD011810-sec-0168"> <h3 class="title" id="CD011810-sec-0168">Potential biases in the review process</h3> <p>The search was based on Cochrane Schizophrenia's Trials Register. There may be some unpublished trials that we are not aware of. At the time this review's trials were published there was pharmaceutical industry interest in the findings and this could have led to publication or reporting bias. </p> </section> <section id="CD011810-sec-0169"> <h3 class="title" id="CD011810-sec-0169">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other systematic reviews on the efficacy of chlorpromazine versus clotiapine for schizophrenia ‐ but would be really interested in finding any. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011810-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Chlorpromazine structure" data-id="CD011810-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Chlorpromazine structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Clotiapine structure" data-id="CD011810-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Clotiapine structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of trial selection from 2016 electronic search" data-id="CD011810-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram of trial selection from 2016 electronic search</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD011810-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD011810-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 1 Mental state: 1a. General ‐ average change scores (PANSS total, high = good)." data-id="CD011810-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 1 Mental state: 1a. General ‐ average change scores (PANSS total, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 2 Mental state: 1b. General ‐ average change scores (S‐scale, high = poor)." data-id="CD011810-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 2 Mental state: 1b. General ‐ average change scores (S‐scale, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 3 Mental state: 2a. Specific ‐ positive symptoms ‐ frequency." data-id="CD011810-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 3 Mental state: 2a. Specific ‐ positive symptoms ‐ frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 4 Mental state: 2b Specific ‐ positive symptoms ‐ average change scores (PANSS positive subscale, high = good)." data-id="CD011810-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 4 Mental state: 2b Specific ‐ positive symptoms ‐ average change scores (PANSS positive subscale, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 5 Mental state: 2c. Specific ‐ negative symptoms ‐ average change scores (PANSS negative subscale, high = good)." data-id="CD011810-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 5 Mental state: 2c. Specific ‐ negative symptoms ‐ average change scores (PANSS negative subscale, high = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 6 Mental state: 2d. Specific ‐ various symptoms ‐ average change score ‐ (S‐Scale, high = poor)." data-id="CD011810-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 6 Mental state: 2d. Specific ‐ various symptoms ‐ average change score ‐ (S‐Scale, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 7 Adverse effects: 1. Central nervous system ‐ short term." data-id="CD011810-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 7 Adverse effects: 1. Central nervous system ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 8 Adverse effects: 2. Movement disorders ‐ short term." data-id="CD011810-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 8 Adverse effects: 2. Movement disorders ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 9 Adverse effects: 3. Various other ‐ short term." data-id="CD011810-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 9 Adverse effects: 3. Various other ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 10 Leaving the study early ‐ short term." data-id="CD011810-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 10 Leaving the study early ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011810-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/urn:x-wiley:14651858:media:CD011810:CD011810-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_t/tCD011810-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chlorpromazine versus Clotiapine, Outcome 11 Service use: discharge from hospital ‐ short term (12 weeks)." data-id="CD011810-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Chlorpromazine versus Clotiapine, Outcome 11 Service use: discharge from hospital ‐ short term (12 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/media/CDSR/CD011810/image_n/nCD011810-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD011810-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggestions for design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described<br/> Blindness: double, tested<br/> Duration: 12 months beyond end of intervention at least<br/> Raters: independent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: people with schizophrenia ‐ however diagnosed*<br/> Age: any<br/> Sex: both<br/> History: any<br/> N = 300** </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Clotiapine: ˜100 mg/day. N = 150<br/> 2. Chlorpromazine: ˜400 mg/day. N = 150 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Global state ‐ relapse, clinically important change</p> <p>Mental state ‐ general ‐ clinically important change in mental state, average change in negative symptoms </p> <p>Adverse effects ‐ incidence of serious adverse events/effects, clinically important extrapyramidal symptoms </p> <p>Leaving the study early ‐ for any reason</p> <p>Cost of care</p> <p>Service outcomes: admitted, number of admissions, length of hospitalisation, discharge, contacts with psychiatric services<br/> Compliance with drugs<br/> Economic evaluations: cost‐effectiveness, cost‐benefit </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>*This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice. </p> <p>**Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Suggestions for design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011810-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chlorpromazine compared to Clotiapine for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chlorpromazine compared with Clotiapine for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> chlorpromazine<br/> <b>Comparison:</b> clotiapine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clotiapine for schizophrenia</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chlorpromazine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important change</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 1a. General symptoms ‐ average change</b> <br/> (PANSS, short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state: average improvement scores in the intervention groups was<br/> <b>11.50 higher</b> <br/> (9.42 to 13.58 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pre‐stated outcome of clinically important change in mental state not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: 2c. Specific ‐ average change score for negative symptoms</b> <br/> (PANSS ‐ negative short term) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>0.97 lower</b> <br/> (2.76 lower to 0.82 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: incidence of serious adverse effects.</b> Movement disorders ‐ dyskinesia ‐short‐term </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.00</b> <br/> (0.13 to 71.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>68<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>243 per 1000</b> <br/> (168 to 354) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> <br/> (46 to 97) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects: clinically significant extrapyramidal symptoms</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early: for any reason</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.68</b> <br/> (0.24 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>158<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>172 per 1000</b> <br/> (31 to 961) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>296 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>181 per 1000</b> <br/> (33 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost of care</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ downgraded by 1: study has an unclear risk of bias for random sequence generation, allocation concealment, or no wash‐out period reported, or source of funding unclear.<br/> <sup>2</sup>Imprecision: serious ‐ downgraded by 1: there are very few participants, number of events small<br/> <sup>3</sup>Publication bias: serious ‐ downgraded by 1: the study results only published in a local Japanese journal.<br/> <sup>4</sup>Inconsistency: serious ‐ downgraded by 1: there was high heterogeneity in the pooled results.<br/> <sup>5</sup>Indirectness: serious ‐ downgraded by 1: not direct measure of prespecified outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chlorpromazine compared to Clotiapine for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011810-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The Cochrane chlorpromazine for people with schizophrenia reviews</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Review title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acetophenazine versus chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0012" title="BazrafshanA , ZareM , OkhovatiM , Shamsi MeimandiM . Acetophenazine versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD011662] ">Bazrafshan 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine dose for people with schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0039" title="LiuX , DeHaanS . Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007778; PUBMED: 19370692] ">Liu 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cessation of medication for people with schizophrenia already stable on chlorpromazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0008" title="AlmerieMQ , AlkhateebH , EssaliA , MatarHE , RezkE . Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD006329; PUBMED: 17253586] ">Almerie 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus atypical antipsychotic drugs for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0048" title="SahaKB , SampsonS , ZamanRU . Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD010631] ">Saha 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus clotiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Current review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus haloperidol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0038" title="LeuchtC , KitzmantelM , KaneJ , LeuchtS , ChuaWLLC . Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; PUBMED: 18254045] ">Leucht 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus metiapine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0053" title="ZareM , BazrafshanA , OkhovatiM , MazhariS , MousaviR . Chlorpromazine versus metiapine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 5. [DOI: 10.1002/14651858.CD011655] ">Zare 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus penfluridol for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0035" title="KhaliliN , VahedianM , NikvarzN , PiriM . Chlorpromazine versus penfluridol for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 8. [DOI: 10.1002/14651858.CD011831] ">Khalili 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus piperacetazine for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0023" title="Eslami ShahrbabakiM , SharafkhaniR , DehnaviehR , ValiL . Chlorpromazine versus piperacetazine for schizophrenia. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011709] ">Eslami 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine versus placebo for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0006" title="AdamsCE , AwadGA , RathboneJ , ThornleyB , Soares‐WeiserK . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3] ">Adams 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chlorpromazine for psychosis induced aggression or agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011810-bbs2-0007" title="AhmedU , JonesH , AdamsCE . Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews2010, Issue 12. [DOI: 10.1002/14651858.CD007445.pub2; PUBMED: 20393959] ">Ahmed 2010</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The Cochrane chlorpromazine for people with schizophrenia reviews</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011810-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mental state: improvement for positive symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcome or subgroup</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Statistical method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Effect estimate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: average scores for improvement of positive symptoms (high score = improvement)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.17 [‐7.98, 12.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.00 [‐6.75, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference (IV, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.36 [3.54, 11.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state: Improved positive symptoms (frequency of marked effects)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 [0.41, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46 [0.15, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 [0.50, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Severe excitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk ratio (M‐H, random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 [0.15, 3.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Mental state: improvement for positive symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/full#CD011810-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011810-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chlorpromazine versus Clotiapine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1a. General ‐ average change scores (PANSS total, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.50 [9.42, 13.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1b. General ‐ average change scores (S‐scale, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.38, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 2a. Specific ‐ positive symptoms ‐ frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.50, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.15, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Severe excitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.15, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 2b Specific ‐ positive symptoms ‐ average change scores (PANSS positive subscale, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.36 [3.54, 11.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐6.75, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2c. Specific ‐ negative symptoms ‐ average change scores (PANSS negative subscale, high = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐2.76, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Deficiency of initiative and apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐2.76, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2d. Specific ‐ various symptoms ‐ average change score ‐ (S‐Scale, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Delusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Hallucination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.46, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Influence of thought</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.17, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Splitting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.09, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1. Central nervous system ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.98, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Somnipathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.63, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Unsteadiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.77, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.42, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2. Movement disorders ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.65, 13.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Parkinsonism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 3. Various other ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Weight gain (not less than 3 kg at the end of study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.71, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Thirst</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.54, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Leaving the study early ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 for any reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.24, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 due to deterioration or adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.51, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Service use: discharge from hospital ‐ short term (12 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.07, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chlorpromazine versus Clotiapine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011810.pub2/references#CD011810-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011810.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011810-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011810-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011810-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011810-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD011810-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011810-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011810\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011810\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011810\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011810\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011810\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011810.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011810.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011810.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011810.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011810.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718402475"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011810.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718402479"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011810.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcf76391f935f',t:'MTc0MDcxODQwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 